CIBC World Keeps 'Buy' on ImClone

Analyst Matthew Geller says the revised drug development deal with Bristol Myers is a strong positive for the company

CIBC World reiterates buy on ImClone (IMCL )/.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.